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ABSTRACT: Aging is the inevitable time-dependent decline in physiological organ function and is a major risk 
factor for cancer development. Due to advances in health care, hygiene control and food availability, life 
expectancy is increasing and the population in most developed countries is shifting to an increasing proportion 
of people at a cancer susceptible age. Mechanisms of aging are also found to occur in carcinogenesis, albeit with 
shared or divergent end-results. It is now clear that aging and cancer development either share or diverge in 
several disease mechanisms. Such mechanisms include the role of genomic instability, telomere attrition, 
epigenetic changes, loss of proteostasis, decreased nutrient sensing and altered metabolism, but also cellular 
senescence and stem cell function. Cancer cells and aged cells are also fundamentally opposite, as cancer cells 
can be thought of as hyperactive cells with advantageous mutations, rapid cell division and increased energy 
consumption, while aged cells are hypoactive with accumulated disadvantageous mutations, cell division 
inability and a decreased ability for energy production and consumption. Nonetheless, aging and cancer are 
tightly interconnected and many of the same strategies and drugs may be used to target both, while in other 
cases antagonistic pleiotrophy come into effect and inhibition of one can be the activation of the other. Cancer 
can be considered an aging disease, though the shared mechanisms underpinning the two processes remain 
unclear. Better understanding of the shared and divergent pathways of aging and cancer is needed. 
 





Aging is an inevitable time-dependent decline in 
physiological organ function and is a major risk factor for 
one of the most significant causes of human morbidity and 
mortality, namely cancer. According to the US National 
Cancer Institute's Surveillance Epidemiology and End 
Results (SEER) Database, 43% of men and 38% of 
women will develop an invasive cancer over a lifetime. 
Among these, 23% of men and 19 % of women will die 
from cancer. More than half of cancers occur in 
individuals older than 70 [1].  
Improvements in healthcare and healthier nutrition 
have increased the average life expectancy over the past 
century. According to the World Health Organization 
(WHO) life expectancy is now exceeding 80 years in most 
developed countries. As the population is aging, cancer is 
becoming an ever more important health burden 
worldwide.  
The underlying mechanism in both cancer and aging is 
the time dependent accumulation of cellular damage [2]. 
Cancer and aging may seem like opposite processes – 
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cancer cells have the ‘gain of function and fitness’ 
whereas aging cells are characterized by a ‘loss of 
function and fitness’ [2]. However, the two traits do share 
many common characteristics (Table 1), for which a 




Table 1.  Hallmarks that are either shared or divergent in aging and cancer. 
 
Feature Aging Cancer 
Genomic instability Increased Increased 















Hyper- of tumor suppressors and 
hypo- of oncogenes 
Complex 















Deregulated nutrient sensing  Inhibition of insulin and mTOR 
signaling increase lifespan 
Inhibition of insulin and mTOR 
signaling is antineoplastic 
Cellular senescence Increased Prevalent in premalignant tumors but 
evaded in fully malignant tumors 
Stem cell  Exhausted Potential nidus for tumorigenesis 
 
1. Genomic instability 
 
One of the immediate common hallmarks to both aging 
and cancer is the occurrence of genomic instability. The 
human DNA is vulnerable to mutagens such as exogenous 
radiation and endogenous free radicals, to which we are 
exposed constantly over a life-time. Indeed, cells in the 
human body undergo cell-division billions of times during 
which the DNA is replicated, each time with the risk of 
introducing or suffering mutational events. Most of these 
inevitable mutations are harmless and the majority is 
corrected by the DNA repair system. However, a certain 
degree of accumulated DNA damage occurs with time [3]. 
The normal mutation rate after repair in the human 
genome is about one mutation per billion bases per 
division, witch means that a 1,000 bp gene has a one in a 
million chance of a single mutation per cell division[4]. 
Genomic instability in key regulator functions is the most 
prominent "enabling hallmark" that leads cancer cells to 
acquire many of the driving cancer traits, such as self 
sufficiency in growth signals and increased metastatic 
potential [5]. Genomic instability is a characteristic of 
almost all human cancers and the rate of mutation is 
higher than in normal cells in order to acquire all the 
mutations needed for tumorigenesis [6]. Indeed, with 
increasing knowledge and lessons learned from whole 
genome sequencing of numerous cancers, the mutation 
rate is known to be overall high yet with different rates 
according to tumor types and site, with some tumors being 
labeled hypermutated [7]. 
 
Lessons from hereditary syndromes 
 
Different mutations in the DNA repair machinery lead to 
hereditary cancers syndromes such as hereditary non-
polyposis colorectal cancer (HNPCC)[8], breast and 
ovarian cancer with hereditary mutations in BRCA1 and 
BRCA2 [9] and familial adenomatous polyposis with an 
almost 100% lifetime risk of colorectal cancer[10]. These 
are just a few examples of a large group of such cancer 
syndromes resulting from mutations in the DNA repair 
machinery, giving rise an increased mutational rate and 
genomic instability. Mutations in the DNA repair 
machinery can also cause progeroid premature aging 
syndromes of which there are many [11]. Werner 
syndrome and Bloom syndrome are progeroid syndromes, 
both of which are caused by mutations in RecQ helicases 
involved in repair of double stranded breaks and telomere 
maintenance [12, 13]. They manifest with cancers at a 
very young age, premature aging signs (greying of hair, 
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loss of organ function and reserve) and a significantly 
reduced lifespan [14]. Cockayne syndrome (CS) and 
Xeroderma Pigmentosum (XP) are two other examples of 
progeroid syndromes, both a result of mutations in the 
nucleotide excision repair system (NER). The NER 
mutation in CS affects only actively transcribed genes 
(TCR-transcription coupled repair) whereas the damage 
in XP affects the whole genome (GGR-global genomic 
repair) [15]. They both manifest with features of 
premature aging, but interestingly only XP manifest with 
increased susceptibility to skin cancer [15]. The 
mechanism behind is still unknown, but it has been 
speculated that it may involve apoptosis of mutated cells 




Figure 1. Lifelong interplay between stem cells in aging and cancer. A simplified model that views aging and cancer from 
the perspective of alterations within the stem and progenitor cell pool. Over the lifespan of an organism, long-lived cells (such 
as stem cells) accumulate DNA damage from a number of stresses including intracellular oxidants generated from normal 
metabolism. The default pathway for such damaged stem cells is to undergo growth arrest, apoptosis or senescence. As more 
and more stem cells withdraw from the proliferative pool, there is a decrease in the overall number and/or functionality of both 
stem and progenitor cells. This decrease predisposes the organism to impaired tissue homeostasis and regenerative capacity and 
could contribute to aging and age-related pathologies. Presumably, some rare cells can escape from this normal default pathway 
by acquiring additional mutations that allow them to continue to proliferate even in the setting of damaged DNA. These 
proliferating but damaged cells might provide the seeds for future malignancies. In this scenario, both cancer and aging result 
primarily from accumulating damage to the stem and progenitor cell compartment. Mutations that allow stem cells to continue 
to proliferate in the setting of normal growth arrest signals such as DNA damage (for example, loss of p16INK4a or reactivation 
of telomerase) would temporarily expand the stem cell pool and hence delay age-related pathologies. Over the long term, these 
mutations would also increase the likelihood of cancer. 
During normal aging, stem cells accumulate damage and subsequent stress-dependent changes, for example, de-repression 
of the CDKN2a (p16INK4a/ARF) locus or telomere shortening. This leads to the increasing abundance of senescent cells (large 
hexagonal cells) within differentiated tissues. Preneoplastic leasions, arising directly from stem cells or from more committed 
cells, undergo rapid proliferation (small cells marked with asterisks). These pre-malignant tumor cells rapidly accumulate 
damage, in part owing to the presence of oncogenes, leading to a higher proportion of tumor cells becoming senescent (cells 
marked as hexagons filled with white color). Tumor progression to full malignancy is favoured when tumor cells acquire 
mutations that impair the senescence program (for example, mutations in Trp53 or CDKN2a). 
Illustration is modified and based upon Finkel T, Serrano M, Blasco MA. The common biology of cancer and aging. 
Nature. 2007 Aug 16;448(7155):767-74. Copyright © 2007. 
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Genomic instability in aging cells 
 
Maintenance of genomic stability appears to be a core 
function to prevent cancer development as well as aging 
processes. Genomic instability and mutations may 
contribute to aging in several ways, ranging from small 
point mutations to large translocations and deletions. In 
somatic cells, it can give rise to disruption of the 
phenotype through alterations in the protein coding 
sequence but probably more common is the alteration of 
regulatory sequences leading eventually to progressive 
decline of organ function due to alterations of the 
proteome and homeostasis [17, 18].  Indeed there is a 
large variation in gene expression among cells in the same 
tissue with age, and in an experiment on mice 
cardiomyocytes in young and old individuals the variation 
was significant in all genes tested nuclear genes which 
included 7 housekeeping genes, 3 heart specific genes and 
2 protease genes [18]. The increased gene heterogeneity 
with age seems to be tissue specific, where for instance 
small intestinal cells accumulated mainly point mutations 
and cardiomyocytes also carried large rearrangements 
[19] This gene heterogeneity is proposed to lead to 
stochastic deregulation of gene expression among 
neighboring cells and lead to aging[18]. Genetic 
instability can also cause aging if the damage is large 
enough to cause apoptosis or senescence of stem cells 




Cancer and aging are in a way rivaling processes [18]. On 
the one hand, cancer is the result of advantageous 
mutations that confers an advantage to the neoplastic cell 
when it comes to growth and metastasis (Fig. 1). On the 
other hand, aging is the result of harmful mutations 
detrimental to the cells physiology or damage leading to 
senescence, apoptosis and eventually depletion of stem 
cells [17, 20, 21]. The idea of antagonistic pleiotrophy 
comes to play where high levels of cell cycle gatekeeper 
proteins – such as p53 – results in senescence and 
apoptosis protecting against harmful mutations and 
tumorigenesis, while low levels allows cells with 
tumorigenic mutations to propagate and promote cancer 
[17, 21]. Genomic instability thus reflects the wear and 
tear on cells over time, leading to controlled cell death and 
loss of tissue in aging. Yet, it also represents the stochastic 
risk of accumulating changes that fosters uncontrolled cell 
division and expansion in cancer, evidenced by the higher 
lifetime cancer risk of tissues requiring many cell 
divisions for homeostasis, indicating that the number one 
cause of tissue cancer variation is just "bad luck" [22]. A 
deeper understanding of genomic instability may thus 
help understand its relation to both aging as a process and 
the role in carcinogenesis with potential for therapeutic 
interventions in both areas.  
 
2. Telomere attrition  
 
Most normal human cells have a limited timespan before 
they undergo controlled cell death (apoptosis). Cells can 
only undergo a limited number of cell divisions before the 
cap ends of the DNA is used up and the cell enters an 
apoptotic program. Apoptosis prevents cells from living 
eternally and accumulating mutations as the older cells get 
replaced. The cap end of the DNA is the telomeres, and 
these functions as sort of ‘clock of life’ for each cell, 
counting down the limited replicative potential [23]. 
Telomere function is disturbed in both aging and cancer 
[24]. 
Telomeres are as such the protective repetitive 
nucleotide sequences located at the end of chromosomes. 
Since the DNA polymerase is incapable of fully 
replicating the termini of the DNA strands, each cell 
division results in a gradual shortening of the 
chromosome ends. Most somatic cells in eukaryotic 
organisms do not express telomerase, an enzyme that can 
elongate the telomeres and thus they will only be capable 
of a limited number of cell divisions before coding DNA 
gets compromised. Telomerase activity is high in both 
stem cells and cancer cells leading to the immortality of 
these cells. To avoid DNA instability in somatic cells, 
they will enter replicative senescence once telomeres 
shorten beyond a certain point and reach the Hayflick 
limit of cell division [23, 25]. The Hayflick limit (named 
after Leonard Hayflick), is based on the observation that 
human fetal cells in cell culture could only divide 40-60 
times and then further cell division would stop. It has later 
been proven that the cause of this is the gradual shortening 
of the telomeres by each division until a critical limit 
where the cells cannot divide further without damaging 
coding DNA [25, 26]. The telomeres are also associated 
with protective proteins important in their regulation [27]. 
Telomere dynamics is an important factor in aging, 
age-related diseases and cancer. Telomere maintenance is 
determined by both inherited genetic factors and non-
genetic factors such as stress, depression, smoking and 
exercise [27].  
Inherited telomere syndromes where single gene 
inactivating mutations occur in telomere maintenance 
components are known. These mutations usually lead to 
short in vivo telomeres. Patients usually have phenotypes 
of accelerated aging such as diabetes, cardiovascular 
disease, hair graying and altered skin pigmentation in 
addition to loss of immune function and susceptibility to 
certain cancers [27, 28]. 
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Telomeres and aging 
 
In the general population, short telomere length have been 
associated with many age-related diseases such as poor 
immune function [29], diabetes [30], cardiovascular 
disease [31, 32], osteoarthritis [33], atrial fibrillation [34] 
and Alzheimer's disease [35].  Short telomere length is 
also associated with earlier death from age-related 
diseases in those over 60 [36], and overexpression of 
telomerase can inhibit aging but at the expense of 
increased tumorigenesis [37, 38]. Telomere length is also 
highly heritable and a study found that heritability counts 
for more than 50% of telomere length, and that sons have 
shorter telomeres than daughters at any given age. It 
showed that first-degree relatives of families with 
exceptional longevity and long telomeres had longer 
telomeres than second-degree relatives and also longer 
than their spouses [39]. 
 
Telomeres and cancer 
 
Telomerase upregulation in cancer cells is a pivotal event 
in cancer cells acquisition of a limitless replicative 
potential as one of the hallmarks of cancer. In 80-90% of 
fully malignant human tumors, the telomerase is 
upregulated compared with normal tissues [27]. This 
enzyme, human telomerase reverse transcriptase (hTERT) 
has the ability to build back on the cap ends that otherwise 
gets shortened by each cell division. By avoiding an ever-
shorter cap end by hTERT, the cell avoids the Hayflick 
limit and does not enter apoptosis. Several studies and 
meta-analyses have examined the association of telomere 
length in blood leukocytes to cancer risk and mortality. 
Some studies showed that telomere attrition and short 
telomeres is a risk factor for cancer development [40-42]. 
The adjusted odds ratio (OR) for bladder cancer was 1.88 
for individuals in the quartile with the shortest telomeres 
as compared with individuals in the quartile with the 
longest telomeres[40]. This also holds true for lung cancer 
(OR=2.39), smoking related cancers (OR=2.25), cancers 
of the digestive system (OR=1.69) and urogenital system 
cancers (OR=1.73). Incidence rates in a 10 year 
population follow up study was 5.1 per 1,000 in the 
longest telomere group, 14.2 in the middle group and 22.5 
in the short telomere group [43]. Other studies show an 
association with cancer mortality [44-46]. Multivariable-
adjusted hazard ratios of early death were 1.31 in 
individuals in the quartile and 1.43 in individuals in the 
decile with the shortest telomeres vs the longest [44], and 
in a large 7-year follow up study on 63,637 individuals the 
multivariable-adjusted hazard ratio of cancer mortality 
was 1.35 for individuals in the shortest vs the longest 
decile [46]. Thus, hTERT may act in some instances as a 
risk-factor for developing cancer, and in other setting as a 
driver for the aggressiveness of cancer. The association 
might be cancer-type specific and some cancers might be 
more dependent on telomerase than others. A meta-
analyses showed stronger association between short 
telomeres and bladder, esophagus, gastric, head and neck, 
ovarian and renal cancers [47]. 
 
Common role in aging and cancer 
 
A recent study showed that age-related telomere attrition 
is faster in those who later developed cancer but that the 
attrition decelerates before cancer diagnoses resulting in 
longer telomeres 3-4 years prior to diagnoses [48]. This 
might represent telomere shortening being involved in 
early carcinogenesis followed by cancer hijacking and 
initiating methods of telomere elongation such as 
telomerase activation [48]. This might also affect blood 
leukocytes, which are major players in cancer 
development and progression. If this is validated in future 
studies, it may point to a potential as an early biomarker 
for cancer detection [48]. Therapeutic manipulation of 
hTERT may also have potential as a cancer-therapy. 
Further, how this can affect aging processes has been 
pursued also from a therapeutic perspective. 
 
3. Epigenetic alterations 
 
Epigenetics are changes in gene expression without 
altering the DNA sequence, such as DNA methylation, 




DNA methylation is a common epigenetic mechanism of 
gene regulation and promoter region hypermethylation is 
associated with gene silencing and hypomethylation is 
associated with increased gene transcription.  
Methylation has been suggested as the predictor of 
human age in many genome wide methylation studies 
[49], but the relationship is complex. An increase in age 
is associated with increasing global hypomethylation, but 
many loci are also hypermethylated, such as many tumor 
suppressor genes [2, 50]. Cells from patients and mice 
with progeroid syndromes also demonstrate methylation 
patterns that mirror those found in normal aging [51]. A 
large meta-analysis of over 13,000 participants showed 
that DNA methylation-based biomarkers, also called 
"epigenetic age", predicts all cause mortality independent 
of chronological age, race and other risk factors. This was 
consistent over all the ethnic groups examined (Non-
Hispanic whites, Hispanic and African American) [52]. 
"Epigenetic age" are robust estimators of chronological 
age described by Horvath [53] and Hannum [54] and is 
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based on levels of methylation on a defined number of 
CpG dinucleotide markers [52]. 
Cancer cells are broadly characterized by 
hypermethylation and silencing of tumor suppressor 
genes including cell cycle regulators p21, p16INK4a, Rb, 
DNA repair genes exemplified by BRCA1 or receptors 
such as retinoic acid receptor (RARB) [55]. Cancer is also 
associated with hypomethylation and activation of proto-
oncogenes and this seems to have a causative role in 
oncogenesis by causing chromosomal instability [56]. As 
an example the hypomethylation of specific long 
interspersed nuclear element-1 (LINE-1) is associated 
with activated proto-oncogenes MET, RAB3IP and 
CHRM3 in metastatic colorectal cancer [57], and 
hypomethylation and activation of the putative proto-
oncogene ELMO3 is associated with lung cancer 
development and metastasis [58].  
Aberrant methylation patterns are observed in almost 
all neoplasms and have potential as molecular markers in 
cancer prevention, prognosis and therapy [55]. Several 
natural compounds, such as resveratrol, green tea and 
curcumin, have shown potential in prevention and 





Histones can be altered by covalent and reversible 
acetylations, methylations, sumolyation, ADP-
ribosylation, ubiquitylation and phosphorylations [55]. 
This will alter the electric charge of amino residues on 
histones and make it bind the negatively charged DNA 
strands tighter or looser, resulting in actively transcribed 
loose euchromatin or the tighter silenced 
heterochromatin. These epigenetic changes also work in 
recruitment of the transcription regulation machinery 
[55]. The modifications can occur at many different spots 
on the histone tails and are controlled by numerous 
enzymes, including methyl transferases, demethylases, 
acetyltransferases, deacetylases. This regulation is very 
complex and involves many different players, but 
numerous studies link histone modification to both aging 
and cancer, and investigation is ongoing concerning drugs 
that can inhibit the enzymes involved. These drugs can 
potentially be used in both cancer therapy and to promote 
healthy aging. Analyses of large sets of sequenced DNA 
from tumors reveal that histone methyl transferases are 
frequently mutated in cancer, and represent 5% of driver 
genes identified in whole genome sequencing in breast 
cancer[60, 61]. This is also a potentially important target 
for drug innervation and many studies are ongoing [61]. 
Aging is also associated with specific complex 
alterations of histones and chromatin distribution. 
Histone-3 lysine-9 trimethylation (H3K9me3) is the 
hallmark of constitutive heterochromatin, and H3K9me2 
is also heterochromatin associated. Aging is associated 
with a decrease or redistribution of the two with loss of 
repression over constitutive heterochromation loci and 
concomitant gain of facultative heterochromatin in other 
genomic regions [62]. H3Kme3 is associated with 
transcription start sites and is associated with active 
transcription, and elevated levels are associated with 
advanced age [62]. These are just a few examples of the 
novel and exciting field of histone modifications as 
related to aging. As we gain a better understanding of the 
field, drugs intervening with regulatory enzymes might be 




Non-coding DNA most importantly represented by 
microRNA also play an important role in gene regulation 
and emerging evidence suggest that they may regulate up 
to 80% of all expressed genes [63]. Evidence suggests that 
microRNA involvement in the regulation of many 
important pathways in both aging and cancer. For 
example, senescence, IGF-1 and mammalian target of 
rapamycin (mTOR) [49].  
Aberrant expression of many different microRNA can 
contribute to both the development and prognosis of 
various cancer types [55]. As an example, many members 
of the let-7 family are down-regulated in breast cancer and 
this is associated with upregulation of estrogen receptors 
(ER). Experimental over-expression of let-7 in ER 
positive breast cancer tissue caused inhibition of cell 
proliferation and induction of apoptosis [55, 64].  
The miR-17-92 cluster comprises 6 miRNAs which 
are implicated in both cancer and aging. The deletion of 
these is neonataly lethal in mice and they are regulators of 
development and aging. The expression is downregulated 
with age and overexpression is associated with life 
extension in mice [65]. The cluster is also protective 
against a variety of age related pathologies such as heart 
disease, neurodegenerative disease and osteoporosis [65]. 
A pleiotrophic role is suggested as it is involved in cells 
senescence and aging, but upregulation promotes 
oncogenic transformation and plasma levels are increased 
in a wide range of tumors suggesting a role as a potential 
alarm marker [65]. 
Antisense RNA can be used to interfere with miRNA 
and these have showed promise in oncological therapy of 
hepatocellular carcinoma, pancreatic cancer, glioblastoma 
and breast cancer in combination with radiochemotherapy 
[66]. 
CircularRNA (circRNA) are circular RNA sequences 
of approximately 100 nucleotides that have been known 
for a long time but little is known about their function. 
Emerging evidence shows that these RNA have important 
Aunan J. R., et al                                                                                                                Hallmarks of Aging and Cancer 
Aging and Disease • Volume 8, Number 5, October 2017                                                                               634 
 
functions in a wide range of processes such as cell 
senescence, apoptosis, cell cycle regulation and aging 
among many others. They are also involved in cell 
signaling and can have a protective role in colorectal 
cancer [67] and expression is altered in many other 
malignancies [68]. 
 
4. Loss of proteostasis 
 
Proteostasis is the homeostasis of our proteome; a healthy 
protein turnover. The proteostasis network consist of 
chaperone-mediated folding, proteasomal degradation 
and autophagy. Failure of proteostasis can lead to the 
accumulation and deposition of misfolded and proteo-
toxic polypeptide aggregates compromising the vitality of 
the cell.  This is the hallmark of many age-related 
diseases, especially neurodegenerative diseases such as 
Alzheimer’s or Parkinson's disease, and also cataracts, the 
most common cause of blindness in the world which 
primarily affect the elderly [69, 70]. There is a progressive 
deterioration in proteostasis with age and almost all 
tissues of the aged organism will have a certain 
accumulation of protein aggregates and inclusions [71]. 
Proteostasis is also involved in cancer development and 
research into drugs targeting proteostasis is being 
investigated as potential new antineoplastic drugs and 
many have also entered the clinics. 
 
Molecular chaperones (heat shock proteins) 
 
Chaperones and co-chaperones are evolutionary 
conserved small molecules that aid in the folding and 
refolding of polypeptides to functional proteins, or direct 
them to the degradation system if such folding cannot be 
accomplished. During evolution the chaperones also 
acquired extra chaperoning roles, such as immune system 
regulation, cell differentiation, gene expression, DNA 
replication, signal transduction, programmed cell death, 
cellular senescence and carcinogenesis [72]. The most 
important of these chaperones is the heat shock proteins 
(HSP) whose transcription is up-regulated during cellular 
stress. 
  Aging is associated with impaired induction of the 
chaperone system in response to stresses and as a result 
accumulation of misfolded proteins occur [73]. 
Overexpression of chaperones is associated with extended 
longevity in lab animals [2], so the induction of HSP could 
potentially halt aging by refolding the damaged 
accumulated proteins [74]. HSP levels are decreased with 
age in most tissues including neurons, and so is HSF (heat 
shock factor), the principal transcription factor for the heat 
shock proteins [74]. HSP are not only involved as a 
folding assistant, but can also guide proteins to the 
lysosomes in a process called chaperone mediated 
autophagy. This process is induced by starvation or 
oxidative stress [74]. This is believed to be one of the 
mechanisms by which starvation prolongs lifespan, by 
increasing protein turnover and causing damaged proteins 
to be degraded [75]. The dysregulation of the chaperone 
system with age is also proposed to cause dysregulation 
of the immune system as the two are tightly associated 
[76]. 
The chaperone system is also implicated in cancer 
development and progression, but instead of reduced 
activity such as in aging, over-activity seems to be the 
norm. The level of most heat shock proteins are 
significantly upregulated in most cancers tested, including 
colon, cervix and prostate [72]. Chaperones have been 
implicated in a range of human cancer types, being 
involved in various oncogenic processes such as cell 
proliferation, invasiveness, induction of neo-
angiogenesis, the metastatic process, and in induction of 
immune tolerance [72]. This is achieved by mechanisms 
such as association with important signal transduction 
pathway members including HER2, ALK, EGFR and 
BRAF, the dysregulation of which is associated with 
several cancers [72, 77].   
  Chaperones can also bind and inactivate tumor 
suppressors (such as p53), stabilize VEGF and nitric oxide 
synthase involved in angiogenesis and can be secreted 
acting as signaling molecules [72]. Protection against 
tumor suppressive amyloidogenesis is also an important 
feature [78]. The over-expression of several HSPs is also 
associated with a poor prognosis in many cancers [72, 78]. 
   HSPs can inhibit the induction of cellular senescence 
and apoptosis and, in effect, protect the cancer cells from 
chemotherapy [79]. As a result, their importance in cancer 
development and progression has led to a workload of 
research on chaperones as a target for cancer therapy.  
    Several inhibitors of HSP90 are currently in clinical 
trials and making their way into the clinics. These can be 
used in monotherapy or in combination with 
chemotherapy and have shown striking potential against 
subgroups of non-small cell lung cancer, and promising 
results in breast cancer, gastrointestinal stromal tumors 
(GISTs), melanoma and some hematological 
malignancies [80]. In preclinical trials the combination of 
a HSP90 inhibitor with radiotherapy shows great results 
in the usually radiochemotherapy resistant hepatocellular 
carcinoma[81]. HSP70 inhibitors have shown preclinical 
anti-cancer effects in multiple myeloma [82], and a 
HSP27 inhibitor has shown effect in castration resistant 
prostate cancer and is now undergoing phase 2 clinical 
trial [83]. Chaperone targeting drugs show promise as a 
new group within cancer therapy and a several avenues of 
research is currently ongoing.  
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Figure 2. The dual role of autophagy in cancer. Examples of mechanisms that are related to either tumor suppression or 






The ubiquitin-proteasome and autophagy-lysosome 
pathways are the main proteolytic systems and these are 
also essential for proteostasis. Proteasome activation 
delays aging in vivo and vitro in a variety of laboratory 
organisms [84]. Proteasome activity is also high in 
centenarians and has been postulated as one of the 
mechanisms for their healthy aging [85]. Compounds that 
increase proteasome activity such as dietary fatty acids, 
pollen, algae extract, spices and several synthetic 
compounds have resulted in prolonged and healthy living 
in laboratory animals and human cell lines [85]. 
 Proteasome inhibitors have already made it to the 
clinics as treatment mainly for multiple myeloma and 
different lymphomas. Bortezomib (Velcade) was the first 
inhibitor approved in 2003, but several second generation 
inhibitors have emerged since Bortezomib has been a 
staple for multiple myeloma treatment at all stages of the 
disease and is commonly used in combination with strong 
glucocorticoids and chemotherapeutics [86]. Bortezomib 
is currently also used in mantle cell lymphoma and has 




Autophagy is the lysosome-mediated way of degradation 
of misfolded proteins, damaged organelles and 
intracellular pathogens. Autophagy is the major 
intracellular degradation system by which cytoplasmic 
materials are delivered to and degraded in the lysosome. 
Although removal and degradation of cellular products is 
important, the sole purpose of autophagy is not the simple 
elimination of materials. Rather, autophagy also serves as 
a dynamic recycling system that produces new building 
blocks and energy for cellular renovation and homeostasis 
[87]. After autophagy, the resultant degradation products 
can be used for different purposes, such as new protein 
synthesis, energy production, and gluconeogenesis. 
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Autophagy and aging - role of caloric restriction 
 
Caloric restriction (usually by 20-40% of ad libitum 
intake) without malnutrition has long been one of the most 
established and potent ways of life extension and many of 
the mechanisms thought to mediate this effect converge 
on autophagy. Studies in mice have revealed that mice fed 
a 55-65% caloric restricted diet through their life 
exhibited a 35-65% greater mean and maximal lifespan 
than mice eating a non-purified-ad libitum diet [88, 89]. 
Prolonged caloric restriction has also been found to delay 
onset of age related diseases such as diabetes and cancer 
in calorie restricted rodents and non-human primates [88]. 
Caloric restriction in overweight humans has been shown 
to reduce cardiac risk factors, improve insulin sensitivity, 
enhance mitochondrial function and reduce oxidative 
damage do DNA [88]. It is still to early to conclude on a 
life extending effect in humans but evidence of the health 
benefits is emerging. Calorie restriction works by several 
mechanisms. It has antioxidative and anti-inflammatory 
actions through COX, NF-kB and MAPK pathway 
inhibition [90]. Calorie restriction also alters global DNA 
methylation and upregulates histone deacetylases among 
them the sirtuins, causing chromatin alterations [90]. The 
sirtuins also have effects through wide interaction with 
many transcription factors still not fully characterized 
[90]. Calorie restriction is also a potent way of inhibiting 
of cancer initiation and progression through the same 
pathways as above and also through a decrease in mTOR 
signaling, decreased growth factor signaling and 
decreased vascular perturbations [91]. Caloric restriction 
upregulates several signaling pathways that mediate 
increased lysosome-autophagy activity, including mTOR 
inhibition and sirtuin upregulation [92]. Autophagy is 
sufficient to extend lifespan in several laboratory animals 
including mice, and knockdown of several autophagy 
components abolishes this effect [93]. Autophagy gene 
polymorphism has been linked to age-related diseases 
such as osteoarthritis, senile osteoporosis and 
neurodegenerative disease [49]. Several compounds have 
been discovered to increase autophagy, extend lifespan 
and improve outcome in age related neurodegenerative 
diseases in model organisms. These include the mTOR 
inhibitor Rapamycin, the acetyltransferase inhibitor 
Spermidine and resveratrol, a compound isolated from the 
skin of red grapes and popularized as the central 
compound in the wine theory of the French paradox [49, 
94].  
 
Autophagy and cancer – a dual role 
 
Autophagy is upregulated and important for survival in 
most cancers, especially after treatment as most 
anticancer drugs will result in upregulation, giving rise to 
the theory that autophagy works as a way of chemo-
resistance [95]. Autophagy works by degrading defective 
mitochondria and also through the degradation of fats and 
proteins providing the high energy requiring tumor cells 
with energy and glutamine [96]. Several lines of evidence 
suggest that autophagy has a dual role in carcinogenesis – 
on the one side through mechanisms that are promoting 
tumor growth, while on the other side inducing tumor 
suppression effects (Fig. 2). Knockout of autophagy in 
genetically engineered mouse models with NSCLC and 
pancreatic cancers leads to the transformation of 
malignant tumors to benign rare oncocytomas, tumors 
with accumulated defective mitochondria [96].  
Since treatment with anticancer drugs upregulated 
autophagy many studies have been performed on cancer 
cell lines and experimental animals where 
chemotherapeutics has been given together with 
chloroquine or hydroxychloroquine, which are anti-
malaria drugs used to inhibit autophagy. The combination 
shows increased cytotoxicity and apoptosis for the cancer 
cells in most cases [95]. Notably, these drugs might also 
be incorporated into the growing arsenal on antineoplastic 
drugs in the future. 
 
5. Deregulated nutrient sensing and mitochondrial 
dysfunction   
 
One of the earliest and most effective paths to extended 
longevity in a variety of laboratory animals including 
primates is calorie restriction, and nutrition and 
metabolism has long been connected to cancer as well. 
Common features of human aging includes increased 
visceral fat and decreased lean mass, insulin resistance, 
and increase in muscle ragged red fibers (accumulation of 
defective mitochondria within muscle cells) [49]. These 
features are related to diseases of old age, including 
cancer. 
 
Insulin like growth factor 
 
Insulin like growth factor (IGF-1) is upregulated in 
response to growth hormone and signals through the same 
pathway as insulin. Together the signaling pathways are 
called IIS (insulin and IGF-1 signaling) pathway and is 
the most conserved aging controlling pathway in 
evolution and has many targets among them AKT, 
mTOR, RAS and FOXO [2, 97]. Genetic polymorphisms 
or mutations attenuating signaling at any level of this 
signaling pathway has been linked to increased longevity, 
and the pathway is linked to the beneficial effects of 
caloric restriction [98]. Insulin and IGF signaling has been 
shown to inhibit apoptosis and promote cell proliferation 
and division potentially extending the lifespan of 
genetically altered cells and has been linked to colorectal 
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cancer, prostate cancer and breast cancer [97, 99]. 
Circulating levels of IGF1 and IGFBP3 has been linked to 
all cause mortality in men with advances prostate cancer 
and risk of developing prostate cancer [97]. Circulating 
levels of IGF1 and IGFBP3 have also been linked to all 
cause mortality and development of breast cancer in some 
reports, but studies are conflicting [97, 100]. High 
circulating IGF1 has also been linked to more locally 
advanced stages of colorectal cancer and less 
differentiated cases of colorectal cancer [97]. While an 
overall role in cancer appears present, the magnitude and 





Diabetes mellitus type 2 is the number 3 risk factor for 
pancreatic cancer and is also linked to endometrial cancer 
[101, 102]. In a large meta analysis intentional weight loss 
with and without bariatric surgery was also linked to a 
significant reduction in cancer risk, but this was mostly 
attributed to a reduction in estrogen and pro-inflammatory 
cytokines, as the results for IGF were inconsistent [103]. 
Ongoing investigations look for the potential for IIS 
inhibiting drugs in cancer therapy with mixed results, as 
reviewed elsewhere [104]. 
 
The mTOR and AMP Kinase (AMPK) pathways 
 
Other important nutrient sensing pathway participants 
involved in both aging and cancer are mTOR and AMP 
Kinase (AMPK). The mTOR plays a key role in cellular 
metabolism, growth and proliferation [105]. Genetic 
down-regulation of the mTOR pathway extends longevity 
in a wide range of laboratory animals, and treatment with 
rapamycin in mice extends longevity and is considered the 
most robust chemical life extender in mammals [2]. 
Several mTOR inhibitors have entered the clinics 
primarily used as immunosuppressants and antineoplastic 
drugs. Up-regulated mTOR signaling is involved in the 
development, progression and metastasis of many 
different cancers including colorectal, prostate and breast 
cancer [105]. Temsirolimus, an mTOR inhibitor is 
currently used in treatment of advanced renal cell 
carcinoma and mantle cell lymphoma. Evrolimus is used 
in renal cell carcinoma, pancreatic neuroendocrine 
tumors, nonfunctional NET (neuroendocrine) tumors of 
gastrointestinal and lung origin [106], certain 
astrocytomas and hormone receptor positive advanced 
breast cancer. Studies investigating new indications are 
ongoing and second-generation mTOR inhibitors are 
underway. Metformin, a medicine commonly used in the 
treatment of diabetes mellitus type 2 activates AMP 
kinase, which causes inhibition of the mTOR pathway 
among other effects. Metformin inhibits proliferation of a 
wide range of cancer cell lines in vitro and significantly 
extends lifespan in various laboratory animals [2, 107, 
108]. 
  
6. Cellular senescence 
 
Cellular senescence is the process in which a cell 
irreversibly stops dividing and undergoes certain 
phenotypic alterations including chromatin changes and 
alterations in the secretome [49]. Cellular senescence can 
be triggered by various stress mechanisms such as 
telomere shortening, oncogene activation, DNA damage 
response (DDR) pathway and activation of p16INK4a. The 
critical executioners of cellular senescence seems to be 
Retinoblastoma 1 (Rb1) and p53, both of which are tumor 
suppressor proteins involved in carcinogenesis [109]. 
Data indicates that cells can memorize mitogenic stimuli 
and cell division history through progressive de-
repression of CDKN2A and transcription of cell cycle 
inhibitors p16INK4a and p19ARF, which ultimately leads to 
increased p53 and Rb1 causing cell senescence. This 
memory seems to involve epigenetic changes through 
Polycomb complexes and histone methylations [109]. 
Senescence works as an anticancer mechanism by 
inhibiting the proliferation of cells with telomere attrition 
and cells overexpressing oncogenes. This 
oncosuppressive effect is supported by the many 
senescent cells found in premalignant lesions [110]. This 
might be a protective effect early in life limiting the 
expansion of mutated and potentially harmful cell lines, 
but the accumulation of such senescent cells with age can 
be deleterious [111]. Senescence can also have tumor 
promoting effects [112], since senescent cells are also 
avid secretors of proinflammatorly cytokines and growth 
factors, known as the senescence associated secretory 
phenotype (SASP) and this secretion has been implicated 
in both cancer development and aging [49, 112]. Among 
these are proinflammatory factors TNF-α, IL-6, matrix 
metalloproteinases and monocyte chemoattractant 
protein-1, and growth factors such as FGF, EGF and 
VEGF [111, 113]. Inflammation is a well-known risk 
factor for many malignancies including tumorigenesis of 
the lung, initiated by pollution and smoke and perhaps 
involving miRNA regulation [114, 115]. Senescent cells 
are usually removed by immune surveillance and 
phagocytosis, but seem to gradually accumulate with age, 
most likely due to increased production as well as 
decreased elimination due to immunosenescence [49]. 
There is increasing evidence that senescence is involved 
in aging and as such aging might be the cost of cancer 
protection [112]. 
Both p16INK4a and p53 are potent inducers of 
senescence and demonstrate antagonistic pleiotrophy in 
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which protection against cancer leads to accelerated aging 
[112, 116]. p16INK4a expression is markedly upregulated 
with age in humans and rodents and is a remarkably good 
biomarker of aging [109]. Mice lacking p16INK4a 
demonstrated higher regenerative capacity but at the 
expense of increased incidence of spontaneous and 
carcinogen induced cancers [112]. The INK4a/ARF locus 
was the genetic locus most strongly linked to age 
associated diseases in a genome wide association study 
[117], and conditional expression of p16INK4a in mice lead 
to many of the physiological hallmarks of aging [118]. 
Removal of INK4a expressing senescent cells in mice 
delays onset and halts progression of aging and associated 
diseases [119]. 
 
7. Stem cells 
 
Stem cells have an important role throughout our lives 
(Fig. 1), first during development and growth, and then in 
maintenance and repair during adult life. Stem cell 
depletion and dysfunction can give rise to many of the 
pathophysiological processes observed with aging, such 
as anemia and immunosenescence due to dysfunctional 
hematological stem cells [120], osteoporosis due to (loss 
of) mesenchymal stem cells [121] or sarcopenia due to 
(loss of) muscle stem cells [122]. Studies show that aging 
is accompanied with a diminished capacity to maintain 
homeostasis and to repair tissues after injury. When this 
ensues to the point that the tissues are no longer able to 
maintain homeostasis and adequate repair, physiologic 
decline and aging ensues [123]. 
Cancer is a disease associated with aging and the 
pathogenesis of cancer consists of multiple mutagenic 
events, and as such long lived stem cells seems to be the 
only cells capable of serving as such reservoirs. Stem cells 
represent the ideal cellular targets for the accumulation of 
precancerous lesions [123].   
Cancer and aging might represent the two possible 
endpoints of a stem cells exposed to enough mutagenic 
hits (Fig. 1). Throughout life mutagenic hits will occur 
and if these cause genetic instability tumor suppressors 
such as p16INK4a will cause cell cycle arrest, and apoptosis 
or senescence. If however the tumor suppressors fail, 
cancer may result [109]. In fact, hematopoetic stem cells 
of old mice undergo fewer divisions than those of young 
mice and this correlated with the accumulated DNA 
damage and expression of p16INK4a [2, 124].  
Stem cells also seems to mature and change quality as 
the organisms develop and hematological stems cells of 
young mice can give rice to different T and B cells subsets 
than old mice. The transcriptome is also fundamentally 
different between old and young cells. Lastly in young 
mice the lymphoid lineages predominate while this is 
skewed towards the myeloid lineage with age. This is also 





Aging is the inevitable path of life and cancer is usually 
thought of as an age-related disease, as cancer is 
increasingly common with advanced age and relatively 
rare in the young except leukemia. It is therefore not 
surprising that the two share many hallmarks. However, 
cancers cells and aged cells are also fundamentally 
opposite as cancer cells can be thought of as hyperactive 
cells with advantageous mutations, rapid cell division and 
increased energy consumption, while aged cells are 
hypoactive with accumulated disadvantageous mutations, 
cells division inability and a decreased ability for energy 
production and consumption. This is also reflected in the 
hallmarks of the two.  
Aging and cancer share many hallmarks such as 
genomic instability, although cancer cells often benefit 
from mutations, other cells accumulate damaging 
mutations resulting in physiological decline and aging. 
Telomere attrition is also a common trait, but cancer cells 
circumvent cell cycle arrest by activating telomerase. 
Epigenetic changes are common in both and research and 
knowledge is accumulating at a rapid pace. There is a 
massive potential in inhibitors of enzymes responsible for 
the covalent modifications to DNA and histones, and also 
to antisense nucleic acid interfering with micro RNA.  
Proteostasis is altered in both and protein aggregate 
accumulation and the toxic effects of it is the hallmark of 
many age-related diseases. Cancer avoids this by 
upregulating chaperone, proteasome and lysosome 
activity. Inhibitors of all pathways are already established 
in oncological treatment and new generations and new 
drugs are in continuous trials and development. 
Deregulated nutrient sensing is common to both and 
interference with the IIS pathway or mTOR pathway and 
AMP kinase pathway activation increase lifespan and 
halts cancer. Many mTOR pathway inhibitors have 
entered the clinics and metformin, a AMPK activator has 
potential both in cancer therapy and healthy aging. 
Cell senescence is one of the hallmarks where cancer 
and aging are fundamentally different as accumulating 
DNA damage usually will cause a upregulation of cell 
cycle inhibitors leading to senescence or apoptosis while 
malignant cells avoid this by generating additional 
mutations such as deletion of tumor suppressors such as 
p16INK4a or p53, an example of antagonistic pleiotrophy.  
  In summary, aging and cancer are interconnected in 
both time and mechanisms and many of the same 
strategies and drugs can be used to target both, while in 
other cases antagonistic pleiotrophy come in to effect and 
inhibition of one can be the activation of the other.  
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